drugset / Trial / NCT00753883

Ezetrol Post-Marketing Study

NCT00753883

Phase 4 Completed 40 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverOpen-labelTreatment

Summary

To compare the lipid lowering efficacy of adding ezetimibe to statin vs. statin alone.

Timeline

Start
2006-07
Primary completion
2008-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ezetimibe Unknown 10 mg
Comparator Simvastatin Small molecule 20 mg

Indications